Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression

Author: Shi Pengcheng   Zha Jie   Guo Xutao   Chen Feili   Fan Zhiping   Huang Fen   Meng Fanyi   Liu Xiaoli   Feng Ru   Xu Bing  

Publisher: Future Medicine

ISSN: 1462-2416

Source: Pharmacogenomics, Vol.14, Iss.1, 2013-01, pp. : 17-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content